文献速递消化系统肿瘤

SIPA1在结直肠癌中的表达及其对生物学行为的影响

[Expression of SIPA1 in colorectal cancer and its impact on its biological behavior].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2025-01-01

研究利用TCGA数据库、5例结直肠癌病理标本及DLD1和HCT116细胞系,探讨SIPA1在结直肠癌中的表达、预后价值及生物学功能。SIPA1在癌组织中高表达且与不良预后相关,敲低SIPA1可抑制肿瘤细胞增殖、侵袭和迁移,并抑制PI3K/AKT/GSK3β通路激活。

要点

  • 结直肠癌组织中SIPA1 mRNA和蛋白表达高于癌旁正常组织。
  • SIPA1高表达组总生存低于低表达组,且与淋巴结侵袭和N分期相关。
  • 敲低SIPA1可抑制结直肠癌细胞增殖、侵袭、迁移及裸鼠移植瘤生长。

核心结论

  • SIPA1在结直肠癌中高表达且与不良预后相关,可能通过调控PI3K/AKT/GSK3β信号通路影响肿瘤细胞增殖和迁移能力。

研究设计与样本

  • 研究利用TCGA数据库分析SIPA1差异表达、生存分析、ROC曲线和预后校正曲线。
  • 选取2023年3月1日至2024年5月1日南通大学附属医院组织标本库中5例结直肠癌患者的癌组织和癌旁正常组织制作组织芯片,行免疫组化和Western blot验证。
  • 在结直肠癌细胞系DLD1和HCT116中构建SIPA1稳定敲低细胞系,进行细胞增殖、侵袭、迁移实验。
  • 通过裸鼠皮下植瘤实验在体内验证SIPA1对结直肠癌细胞增殖能力的影响。
  • 利用通路富集分析探究SIPA1潜在促肿瘤机制,并用Western blot验证;加入PI3K激活剂后检测肿瘤细胞增殖、侵袭和迁移。

主要发现

  • TCGA数据库显示结直肠癌组织中SIPA1 mRNA表达高于癌旁正常组织(P<0.05),SIPA1高表达组总生存低于低表达组(P<0.001)。
  • SIPA1表达与淋巴结侵袭(P<0.001)和N分期(P<0.05)相关;SIPA1预测5年生存率的曲线下面积=0.700,模型预测性能较准确(P<0.001)。
  • Western blot显示结直肠癌肿瘤组织中SIPA1蛋白表达升高(P<0.001),免疫组化显示肿瘤组织SIPA1染色评分更高。
  • DLD1和HCT116细胞中,SIPA1敲低组吸光度值分别为0.89±0.01和0.72±0.01,低于对照组1.57±0.02和1.31±0.03(均P<0.001);敲低组迁移细胞数分别为(197.93±16.64)个和(171.83±12.49)个,少于对照组(518.48±29.15)个和(446.00±21.81)个(均P<0.001);敲低组细胞迁移率分别为(0.32±0.01)%和(0.28±0.01)%,低于对照组(0.61±0.01)%和(0.75±0.01)%(均P<0.001)。
  • 裸鼠皮下植瘤实验中,敲低SIPA1组肿瘤体积(460.35±57.47)mm³、重量(0.76±0.11)g,低于对照组体积(1 177.55±208.24)mm³、重量(1.43±0.08)g(均P<0.05)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objectives: To investigate the expression of signal-induced proliferation-associated 1 (SIPA1) in colorectal cancer tissues and its relationship with patient prognosis. To explore the effects of SIPA1 on proliferation and migration abilities, as well as the possible molecular mechanisms. Methods: Using The Cancer Genome Atlas (TCGA) database to analyze the differential expression of SIPA1 and conduct survival analysis. Then, plotting receiver operating characteristic curve (ROC) and prognosis calibration curve analysis to assess the predictive capability and accuracy of SIPA1 for patient prognosis. Subsequently, verifying the expression levels of SIPA1 in tumor tissues and adjacent normal tissues using immunohistochemistry (IHC) and western blot (WB) assays(from March 1, 2023, to May 1, 2024, pathological specimens of five colorectal cancer patients were selected from the tissue bank of affiliated hospital of Nantong University. tissue microarrays were constructed using both cancerous tissues and adjacent normal tissues), and exploring the correlation between SIPA1 and clinical pathological parameters. Next, establishing SIPA1 stable knockdown cell lines in colorectal cancer cell lines DLD1 and HCT116, and assessing the biological behavior changes of tumor cells after SIPA1 knockdown through cell proliferation, invasion, and migration experiments. Validating the impact of SIPA1 on colorectal cancer cell proliferation in vivo through subcutaneous xenograft experiments in nude mice. Exploring the potential pro-tumor mechanisms of SIPA1 through pathway enrichment analysis, and confirming these using WB experiments. The proliferation, invasion and migration of tumor cells were detected after adding PI3K activator. Lastly, conducting correlation analysis between SIPA1 and immune checkpoint, as well as the association with immune cells in the tumor microenvironment. Results: Differential analysis showed that mRNA expression of SIPA1 in colorectal cancer tissues was significantly higher than that in adjacent normal tissues (P<0.05). Prognostic analysis indicated that patients with high expression of SIPA1 had poor overall survival (P<0.001), and the expression level of SIPA1was correlated with lymph node invasion (P<0.001) and N stage (P<0.05). ROC curve and prognosis calibration curve suggest that SIPA1 can effectively predict five-year survival rate of patients (AUC=0.7), and the predictive performance of the model is relatively accurate (P<0.001). WB experiments showed a significant increase in the expression level of SIPA1 protein in colorectal cancer specimens (P<0.001). Immunohistochemistry results indicated higher staining scores of SIPA1 in tumor tissues. In vitro experiments demonstrated that SIPA1 knockdown significantly inhibited the proliferation, invasion, and migration capabilities of colorectal cancer cells. In DLD1 and HCT116 cells, the SIPA1-knockdown group exhibited significantly lower absorbance compared to the control group (0.89±0.01 vs. 1.57±0.02 and 0.72±0.01 vs. 1.31±0.03, respectively, both P<0.001). The SIPA1-knockdown group also demonstrated a reduced number of migrated cells relative to the control group (197.93±16.64 vs. 518.48±29.15 and 171.83±12.49 vs. 446.00±21.81, respectively, both P<0.001). Furthermore, the cell wound-healing rate was significantly lower in the SIPA1-knockdown group than that in the control group [(0.32±0.01)% vs. (0.61±0.01)% and (0.28±0.01)% vs. (0.75±0.01)%, respectively, both P<0.001]. In vivo animal experiments suggested that SIPA1 knockdown could inhibit tumor growth [(460.35±57.47) mm³ vs (1 177.55±208.24)mm³, (0.76±0.11)g vs (1.43±0.08)g, P<0.05]. Pathway enrichment analysis revealed significant enrichment of the receptor tyrosine kinase signaling pathway, and SIPA1 knockdown could inhibit the activation of the phosphatidylinositide 3-kinases (PI3K)/protein kinase B (PKB)/glycogen synthase kinase-3β (GSK3β) signaling pathway. The PI3K activator reversed the inhibitory effect of SIPA1 silencing on tumor cell proliferation, invasion and migration. Correlation analysis indicated that high expression of SIPA1 was associated with immune checkpoints and various immunosuppressive cells (all P<0.05). Conclusions: SIPA1 is highly expressed in colorectal cancer and associated with poor prognosis. SIPA1 may affect the proliferation and migration abilities of tumor cells by regulating the PI3K/AKT/GSK3β signaling pathway. 目的: 探讨信号诱导增殖相关蛋白1(SIPA1)在结直肠癌组织中的表达及其与患者预后的关系,分析SIPA1对结直肠癌肿瘤细胞增殖迁移能力的影响及可能的分子机制。 方法: 使用癌症基因组图谱(TCGA)数据库分析结直肠癌组织及癌旁正常组织中SIPA1的表达,并进行生存分析。采用受试者操作特征(ROC)曲线和预后校正曲线评估SIPA1对预后情况的预测能力以及准确性。免疫组化染色和Western blot验证肿瘤组织和癌旁正常组织中SIPA1蛋白的表达水平。选取2023年3月1日至2024年5月1日南通大学附属医院组织标本库中5例结直肠癌患者的病理标本,取癌组织和癌旁正常组织制作组织芯片。分析SIPA1与临床病理参数之间的相关性。在结直肠癌细胞系DLD1和HCT116中构建SIPA1稳定敲低细胞系,通过细胞增殖、侵袭、迁移实验检测敲低SIPA1后细胞生物学行为变化。通过裸鼠皮下植瘤实验,在体内验证SIPA1对结直肠癌细胞增殖能力的影响。利用通路富集分析,探究SIPA1潜在的促肿瘤机制,Western blot实验进行验证。SIPA1和免疫检查点以及微环境中免疫细胞之间的关联采用相关性分析。 结果: TCGA数据库结果显示,结直肠癌组织中SIPA1 mRNA表达水平高于癌旁正常组织(P<0.05),SIPA1高表达组患者的总生存时间低于低表达组患者(P<0.001),SIPA1的表达与淋巴结侵袭和N分期有关(P<0.05)。ROC曲线和预后校准曲线提示,SIPA1可以较好地预测患者5年生存率(曲线下面积=0.700),且模型的预测性能较为准确(P<0.001)。Western blot实验结果显示,结直肠癌肿瘤组织中SIPA1蛋白的表达水平升高(P<0.001)。免疫组化结果显示,结直肠癌肿瘤组织中SIPA1的染色评分更高。体外实验表明,在DLD1和HCT116细胞中,SIPA1敲低组的吸光度值(分别为0.89±0.01和0.72±0.01)低于对照组(分别为1.57±0.02和1.31±0.03,均P<0.001);SIPA1敲低组的迁移细胞数[分别为(197.93±16.64)个和(171.83±12.49)个]少于对照组[分别为(518.48±29.15)个和(446.00±21.81)个,均P<0.001];SIPA1敲低组的细胞迁移率[分别为(0.32±0.01)%和(0.28±0.01)%]低于对照组[分别为(0.61±0.01)%和(0.75±0.01)%,均P<0.001]。体内动物实验表明,敲低SIPA1可以抑制肿瘤生长[敲低SIPA1组体积(460.35±57.47)mm³,重量(0.76±0.11)g;对照组体积(1 177.55±208.24)mm³,重量(1.43±0.08)g,均P<0.05]。通路富集分析显示,受体酪氨酸激酶信号通路明显富集,敲低SIPA1可以抑制PI3K/ PKB/ GSK3β信号通路的激活。加入PI3K激活剂后可逆转敲低SIPA1对肿瘤细胞增殖、侵袭和迁移能力的抑制作用。相关性分析表明,SIPA1高表达与免疫检查点和多种免疫抑制性细胞相关(均P<0.05)。 结论: SIPA1在结直肠癌中高表达且与不良预后相关,SIPA1可能通过调控PI3K/AKT/GSK3β信号通路影响肿瘤细胞的增殖和迁移能力。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wang NZ, Zhang L, Chen J, et al. [Expression of SIPA1 in colorectal cancer and its impact on its biological behavior]. Zhonghua Zhong Liu Za Zhi. 2025. PMID: 40692252. doi:10.3760/cma.j.cn112152-20240812-00338

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。